Published in Infect Immun on January 19, 2010
Global Epidemiology of Campylobacter Infection. Clin Microbiol Rev (2015) 1.73
Immunology of gut mucosal vaccines. Immunol Rev (2011) 1.59
Factors that explain excretion of enteric pathogens by persons without diarrhea. Clin Infect Dis (2012) 1.09
Pseudaminic acid on Campylobacter jejuni flagella modulates dendritic cell IL-10 expression via Siglec-10 receptor: a novel flagellin-host interaction. J Infect Dis (2014) 0.86
Caught in the act: in vivo development of macrolide resistance to Campylobacter jejuni infection. J Clin Microbiol (2010) 0.85
Outcome of infection of C57BL/6 IL-10(-/-) mice with Campylobacter jejuni strains is correlated with genome content of open reading frames up- and down-regulated in vivo. Microb Pathog (2012) 0.83
High frequency, spontaneous motA mutations in Campylobacter jejuni strain 81-176. PLoS One (2014) 0.83
Campylobacter jejuni-mediated induction of CC and CXC chemokines and chemokine receptors in human dendritic cells. Infect Immun (2012) 0.83
Lack of homologous protection against Campylobacter jejuni CG8421 in a human challenge model. Clin Infect Dis (2013) 0.83
Identification of immunogenic and virulence-associated Campylobacter jejuni proteins. Clin Vaccine Immunol (2011) 0.80
An Evidenced-Based Scale of Disease Severity following Human Challenge with Enteroxigenic Escherichia coli. PLoS One (2016) 0.79
Characterization of Mucosal Immune Responses to Enterotoxigenic Escherichia coli Vaccine Antigens in a Human Challenge Model: Response Profiles after Primary Infection and Homologous Rechallenge with Strain H10407. Clin Vaccine Immunol (2015) 0.78
Peripheral CD4+ T cell cytokine responses following human challenge and re-challenge with Campylobacter jejuni. PLoS One (2014) 0.78
The host-pathogen interaction in Campylobacter jejuni infection of chickens: An understudied aspect that is crucial for effective control. Virulence (2016) 0.75
Insights into Campylobacter jejuni colonization and enteritis using a novel infant rabbit model. Sci Rep (2016) 0.75
Induction of cytokines in different organs after intranasal inoculation of Campylobacter jejuni in mice. Gut Pathog (2012) 0.75
Polyphosphate and associated enzymes as global regulators of stress response and virulence in Campylobacter jejuni. World J Gastroenterol (2016) 0.75
Virulence and Genomic Feature of Multidrug Resistant Campylobacter jejuni Isolated from Broiler Chicken. Front Microbiol (2016) 0.75
Use of Pathogen-Specific Antibody Biomarkers to Estimate Waterborne Infections in Population-Based Settings. Curr Environ Health Rep (2016) 0.75
Campylobacter enteritis: clinical and epidemiologic features. Ann Intern Med (1979) 12.90
Epidemiology of Campylobacter jejuni infections. Epidemiol Rev (1983) 7.06
Experimental Campylobacter jejuni infection in humans. J Infect Dis (1988) 7.05
Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol (2008) 6.06
A point-source outbreak of campylobacteriosis associated with consumption of raw milk. J Infect Dis (1985) 3.81
Duration of infection-derived immunity to cholera. J Infect Dis (1981) 3.60
Human campylobacteriosis in developing countries. Emerg Infect Dis (2002) 3.14
Campylobacter, from obscurity to celebrity. Clin Microbiol Infect (2004) 3.09
Epidemiology of travelers' diarrhea and relative importance of various pathogens. Rev Infect Dis (1990) 2.52
Phase variation of Campylobacter jejuni 81-176 lipooligosaccharide affects ganglioside mimicry and invasiveness in vitro. Infect Immun (2002) 2.28
Incidence of Guillain-Barré syndrome following infection with Campylobacter jejuni. Am J Epidemiol (2001) 1.98
Host-pathogen interactions in Campylobacter infections: the host perspective. Clin Microbiol Rev (2008) 1.76
A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity. Vaccine (1995) 1.74
Campylobacter jejuni-specific serum antibodies are elevated in healthy Bangladeshi children. J Clin Microbiol (1985) 1.67
Structural characterization of Campylobacter jejuni lipooligosaccharide outer cores associated with Guillain-Barre and Miller Fisher syndromes. Infect Immun (2007) 1.60
Persistent Campylobacter jejuni infections in patients infected with the human immunodeficiency virus (HIV). Ann Intern Med (1988) 1.51
Serologic study of two clusters of infection due to Campylobacter jejuni. J Infect Dis (1983) 1.49
Cohort study of intestinal infection with campylobacter in Mexican children. Lancet (1988) 1.46
Pathogenicity and convalescent excretion of Campylobacter in rural Egyptian children. Am J Epidemiol (2001) 1.45
Comprehensive analysis of bacterial risk factors for the development of Guillain-Barre syndrome after Campylobacter jejuni enteritis. J Infect Dis (2006) 1.40
Incidence of Guillain-Barré syndrome among patients with Campylobacter infection: a general practice research database study. J Infect Dis (2006) 1.36
Protection of breast-fed infants against Campylobacter diarrhea by antibodies in human milk. J Pediatr (1990) 1.32
Mucosal and systemic immune responses in humans after primary and booster immunizations with orally administered invasive and noninvasive live attenuated bacteria. Infect Immun (1999) 1.31
Immunity to Campylobacter: its role in risk assessment and epidemiology. Crit Rev Microbiol (2009) 1.29
Influence of strain characteristics and immunity on the epidemiology of Campylobacter infections in Thailand. J Clin Microbiol (1988) 1.27
Immune response to Campylobacter jejuni in a rural community in Thailand. J Infect Dis (1986) 1.26
Campylobacter jejuni bacteremia in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients: comparison of clinical features and review. Clin Infect Dis (1998) 1.26
Ganglioside molecular mimicry and its pathological roles in Guillain-Barré syndrome and related diseases. Infect Immun (2006) 1.24
Campylobacter jejuni induces maturation and cytokine production in human dendritic cells. Infect Immun (2006) 1.22
Immune response to Campylobacter jejuni and Campylobacter coli in a cohort of children from birth to 2 years of age. Infect Immun (1989) 1.20
Dendritic cells from C57BL/6 mice undergo activation and induce Th1-effector cell responses against Campylobacter jejuni. Microbes Infect (2008) 1.19
The influence of immunity on raw milk--associated Campylobacter infection. JAMA (1987) 1.17
Antibody responses to Campylobacter infections determined by an enzyme-linked immunosorbent assay: 2-year follow-up study of 210 patients. Clin Diagn Lab Immunol (2001) 1.12
A reconsideration of the Campylobacter dose-response relation. Epidemiol Infect (2005) 1.10
Active immunity is seen as a reduction in the cell response to oral live vaccine. Vaccine (1991) 1.10
Immunogenicity and protective efficacy of recombinant Campylobacter jejuni flagellum-secreted proteins in mice. Infect Immun (2008) 1.07
Continued decline in the incidence of Campylobacter infections, FoodNet 1996-2006. Foodborne Pathog Dis (2008) 1.07
Carbohydrate mimicry: a new paradigm of autoimmune diseases. Curr Opin Immunol (2005) 1.06
In vivo phase variation and serologic response to lipooligosaccharide of Campylobacter jejuni in experimental human infection. Infect Immun (2004) 1.05
Clinical features of sporadic Campylobacter infections in Norway. Scand J Infect Dis (1992) 1.02
Campylobacter immunity and quantitative excretion rates in Thai children. J Infect Dis (1993) 0.98
Standardization of measurement of immunoglobulin-secreting cells in human peripheral circulation. Clin Diagn Lab Immunol (1997) 0.97
Diagnostic approach to acute diarrheal illness in a military population on training exercises in Thailand, a region of campylobacter hyperendemicity. J Clin Microbiol (2008) 0.97
Microbial food borne pathogens. Campylobacter jejuni. Vet Clin North Am Food Anim Pract (1998) 0.96
New World monkey Aotus nancymae as a model for Campylobacter jejuni infection and immunity. Infect Immun (2006) 0.95
Does age acquired immunity confer selective protection to common serotypes of Campylobacter jejuni? BMC Infect Dis (2005) 0.95
Campylobacter jejuni enteritis. Clin Infect Dis (2001) 0.95
Zoonotic infections in Europe in 2007: a summary of the EFSA-ECDC annual report. Euro Surveill (2009) 0.93
Campylobacter Enteritis and the Guillain-Barré Syndrome. Curr Infect Dis Rep (2001) 0.88
Pre-exposure anti-Campylobacter jejuni immunoglobulin a levels associated with reduced risk of Campylobacter diarrhea in adults traveling to Thailand. Am J Trop Med Hyg (2001) 0.86
Early activation of mucosal dendritic cells and macrophages in acute Campylobacter colitis and cholera: An in vivo study. J Gastroenterol Hepatol (2008) 0.83
Case series study of traveler's diarrhea in U.S. military personnel at Incirlik Air Base, Turkey. Clin Vaccine Immunol (2008) 0.81
The epidemiology of travelers' diarrhea in Incirlik, Turkey: a region with a predominance of heat-stabile toxin producing enterotoxigenic Escherichia coli. Diagn Microbiol Infect Dis (2009) 0.80
Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J Biol Chem (2003) 9.37
Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island. Nat Immunol (2004) 7.22
Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med (2015) 5.86
Traveler's diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen. Clin Infect Dis (2006) 3.05
Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. Lancet (2008) 2.79
Phase variation of Campylobacter jejuni 81-176 lipooligosaccharide affects ganglioside mimicry and invasiveness in vitro. Infect Immun (2002) 2.28
Features of immune senescence in liver transplant recipients with established grafts. Liver Transpl (2010) 2.05
Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. Hepatology (2005) 2.04
Bacterial infections promote T cell recognition of self-glycolipids. Immunity (2005) 1.92
The 'permeome' of the malaria parasite: an overview of the membrane transport proteins of Plasmodium falciparum. Genome Biol (2005) 1.91
The 13-valent pneumococcal conjugate vaccine for invasive pneumococcal disease in Alaska native children: results of a clinical trial. Pediatr Infect Dis J (2013) 1.84
Intact gram-negative Helicobacter pylori, Helicobacter felis, and Helicobacter hepaticus bacteria activate innate immunity via toll-like receptor 2 but not toll-like receptor 4. Infect Immun (2004) 1.72
Evolutionary and functional relationships of colonization factor antigen i and other class 5 adhesive fimbriae of enterotoxigenic Escherichia coli. Infect Immun (2004) 1.68
Prevalence of norovirus among visitors from the United States to Mexico and Guatemala who experience traveler's diarrhea. J Clin Microbiol (2005) 1.67
Genome sequence of a clinical isolate of Campylobacter jejuni from Thailand. Infect Immun (2007) 1.61
Presynaptic Ca2+ channels: a functional patchwork. Trends Neurosci (2003) 1.57
Quality of life up to 30 years following liver transplantation. Liver Transpl (2008) 1.57
The pattern of late mortality in liver transplant recipients in the United Kingdom. Transplantation (2011) 1.57
Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa. Blood (2005) 1.54
Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant. Clin Vaccine Immunol (2011) 1.51
Motivations, outcomes, and characteristics of unspecified (nondirected altruistic) kidney donors in the United Kingdom. Transplantation (2014) 1.49
Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial. Clin Infect Dis (2013) 1.48
A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea. Am J Trop Med Hyg (2006) 1.46
Tumor recurrence following liver transplantation for hepatocellular carcinoma: role of tumor proliferation status. Liver Transpl (2010) 1.44
Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans. Vaccine (2002) 1.41
Broadly protective Shigella vaccine based on type III secretion apparatus proteins. Infect Immun (2011) 1.41
Campylobacter jejuni from patients with Guillain-Barré syndrome preferentially expresses a GD(1a)-like epitope. Infect Immun (2002) 1.40
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine (2013) 1.39
Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pediatrics (2010) 1.36
Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infect Immun (2002) 1.34
Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics (2010) 1.32
CD4 T cells are the only lymphocytes needed to protect mice against rotavirus shedding after intranasal immunization with a chimeric VP6 protein and the adjuvant LT(R192G). J Virol (2002) 1.32
Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice. Neurobiol Dis (2003) 1.32
Enterotoxigenic Escherichia coli with STh and STp genotypes is associated with diarrhea both in children in areas of endemicity and in travelers. J Clin Microbiol (2006) 1.28
Effect of homologous and heterologous prime-boost on the immune response to recombinant plague antigens. Vaccine (2005) 1.27
Options for inactivation, adjuvant, and route of topical administration of a killed, unencapsulated pneumococcal whole-cell vaccine. Clin Vaccine Immunol (2010) 1.25
Helicobacter pylori heat shock protein 60 mediates interleukin-6 production by macrophages via a toll-like receptor (TLR)-2-, TLR-4-, and myeloid differentiation factor 88-independent mechanism. J Biol Chem (2003) 1.23
Safety, tolerability, and lack of antibody responses after administration of a PfCSP DNA malaria vaccine via needle or needle-free jet injection, and comparison of intramuscular and combination intramuscular/intradermal routes. Hum Gene Ther (2002) 1.21
Kinetics of immune responses to influenza virus-like particles and dose-dependence of protection with a single vaccination. J Virol (2009) 1.20
Donor strand complementation governs intersubunit interaction of fimbriae of the alternate chaperone pathway. Mol Microbiol (2007) 1.19
Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study. Vaccine (2007) 1.18
Characterization of the Campylobacter jejuni heptosyltransferase II gene, waaF, provides genetic evidence that extracellular polysaccharide is lipid A core independent. J Bacteriol (2002) 1.18
A deep-rough mutant of Campylobacter jejuni 81-176 is noninvasive for intestinal epithelial cells. Infect Immun (2004) 1.17
Monitoring systemic donor lymphocyte macrochimerism to aid the diagnosis of graft-versus-host disease after liver transplantation. Transplantation (2004) 1.16
Cataract surgery at the Vancouver Eye Care Centre: do patient indications meet provincial clinical practice guidelines? Can J Ophthalmol (2003) 1.15
Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants. Neurobiol Aging (2002) 1.15
Protection against aerosolized Yersinia pestis challenge following homologous and heterologous prime-boost with recombinant plague antigens. Infect Immun (2005) 1.14
The oral, live attenuated enterotoxigenic Escherichia coli vaccine ACE527 reduces the incidence and severity of diarrhea in a human challenge model of diarrheal disease. Clin Vaccine Immunol (2012) 1.14
Acute graft versus host disease following liver transplantation: the enemy within. Am J Transplant (2004) 1.14
Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol (2010) 1.12
Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin. Vaccine (2009) 1.11
Target selection in designing pasteurization processes for shelf-stable high-acid fruit products. Crit Rev Food Sci Nutr (2004) 1.11
Defending the mucosa: adjuvant and carrier formulations for mucosal immunity. Curr Opin Immunol (2011) 1.10
Capsule polysaccharide conjugate vaccine against diarrheal disease caused by Campylobacter jejuni. Infect Immun (2008) 1.09
Oral immunogenicity of human papillomavirus-like particles expressed in potato. J Virol (2003) 1.09
An enzymatic ruler modulates Lewis antigen glycosylation of Helicobacter pylori LPS during persistent infection. Proc Natl Acad Sci U S A (2006) 1.09
Presynaptic and postsynaptic mechanisms underlie paired pulse depression at single GABAergic boutons in rat collicular cultures. J Physiol (2002) 1.08
Refinement of a human challenge model for evaluation of enterotoxigenic Escherichia coli vaccines. Clin Vaccine Immunol (2011) 1.07
Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge. Clin Infect Dis (2006) 1.06
Binding site stoichiometry and the effects of phosphorylation on human alpha1 homomeric glycine receptors. J Physiol (2002) 1.06
Tribbles 3: a novel regulator of TLR2-mediated signaling in response to Helicobacter pylori lipopolysaccharide. J Immunol (2011) 1.05
Anti-ganglioside antibody induction by swine (A/NJ/1976/H1N1) and other influenza vaccines: insights into vaccine-associated Guillain-Barré syndrome. J Infect Dis (2008) 1.05
In vivo phase variation and serologic response to lipooligosaccharide of Campylobacter jejuni in experimental human infection. Infect Immun (2004) 1.05
Intranasal administration of an Escherichia coli-expressed codon-optimized rotavirus VP6 protein induces protection in mice. Protein Expr Purif (2004) 1.03
Lipopolysaccharide diversity evolving in Helicobacter pylori communities through genetic modifications in fucosyltransferases. PLoS One (2008) 1.02
Characterization of a novel fusion protein from IpaB and IpaD of Shigella spp. and its potential as a pan-Shigella vaccine. Infect Immun (2013) 1.02
The discard of deceased donor kidneys in the UK. Clin Transplant (2014) 1.02
A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl (2007) 1.02
Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneum. Infect Immun (2007) 1.01
Characterization of two Campylobacter jejuni strains for use in volunteer experimental-infection studies. Infect Immun (2008) 1.00
Recombinant C fragment of botulinum neurotoxin B serotype (rBoNTB (HC)) immune response and protection in the rhesus monkey. Toxicon (2006) 0.99
Notch ligation by Delta1 inhibits peripheral immune responses to transplantation antigens by a CD8+ cell-dependent mechanism. J Clin Invest (2003) 0.99
Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine. Vaccine (2011) 0.98
Bioencapsulation of the hepatitis B surface antigen and its use as an effective oral immunogen. Vaccine (2012) 0.98
13-Valent pneumococcal conjugate vaccine in older children and adolescents either previously immunized with or naïve to 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J (2014) 0.98
Development of a Bacillus subtilis-based rotavirus vaccine. Clin Vaccine Immunol (2010) 0.98
Antigen-specific memory T cell responses after vaccination with an oral killed cholera vaccine in Bangladeshi children and comparison to responses in patients with naturally acquired cholera. Clin Vaccine Immunol (2012) 0.98
Comparative chemical and biological characterization of the lipopolysaccharides of gastric and enterohepatic helicobacters. Helicobacter (2004) 0.98
Intranasal or oral immunization of inbred and outbred mice with murine or human rotavirus VP6 proteins protects against viral shedding after challenge with murine rotaviruses. Vaccine (2002) 0.98
Variations in Helicobacter pylori lipopolysaccharide to evade the innate immune component surfactant protein D. Infect Immun (2005) 0.98
High prevalence of Helicobacter Species detected in laboratory mouse strains by multiplex PCR-denaturing gradient gel electrophoresis and pyrosequencing. J Clin Microbiol (2004) 0.98
Effect of adjuvants and route of immunizations on the immune response to recombinant plague antigens. Vaccine (2007) 0.97
Safety and immunogenicity of a single oral dose of recombinant double mutant heat-labile toxin derived from enterotoxigenic Escherichia coli. Clin Vaccine Immunol (2013) 0.97
Diagnostic approach to acute diarrheal illness in a military population on training exercises in Thailand, a region of campylobacter hyperendemicity. J Clin Microbiol (2008) 0.97
Comparison of taurine- and glycine-induced conformational changes in the M2-M3 domain of the glycine receptor. J Biol Chem (2004) 0.97
A combination vaccine consisting of three live attenuated enterotoxigenic Escherichia coli strains expressing a range of colonization factors and heat-labile toxin subunit B is well tolerated and immunogenic in a placebo-controlled double-blind phase I trial in healthy adults. Clin Vaccine Immunol (2011) 0.97
IFN-gamma is the only anti-rotavirus cytokine found after in vitro stimulation of memory CD4+ T cells from mice immunized with a chimeric VP6 protein. Viral Immunol (2007) 0.97
Expression of surfactant protein D in the human gastric mucosa and during Helicobacter pylori infection. Infect Immun (2002) 0.97
Comparative safety and immunogenicity of two attenuated enterotoxigenic Escherichia coli vaccine strains in healthy adults. Infect Immun (2006) 0.97